Axsome Therapeutics (AXSM), (BNTX), HLTH Corporation (HLTH), (HOWL), Moderna (MRNA), (NTLA), Novavax (NVAX), Pfizer (PFE), (PLRX), (VXRT), (YMAB) – Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
[ad_1] The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ NTLA lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded…
Inhibikase Shares Shoot Higher As FDA Announced Clearance To Blood-Cell Cancer Study
[ad_1] The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ IKT Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug candidate…
FDA Announced Clearance To Century Therapeutics’ Allogeneic Cell Therapy Candidate Study
[ad_1] Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. SPRC, a specialty clinical-stage…
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
[ad_1] Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being…
Geron Commences Initial-Stage Rare Blood Cancer Combination Study
[ad_1] Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being…